{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:08:53Z","timestamp":1759010933569},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,1,15]],"date-time":"2007-01-15T00:00:00Z","timestamp":1168819200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer. Concern about nevirapine toxicity during pregnancy has emerged over recent years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aims of the study were to document the frequency of cutaneous and hepatic toxicity secondary to nevirapine use during pregnancy and to compare rates in women starting nevirapine <jats:italic>during<\/jats:italic> the current pregnancy with those in women who had commenced nevirapine <jats:italic>prior to<\/jats:italic> the current pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>This was a retrospective, comparative, five\u2010centre study carried out in London, UK, in 1997\u20132003.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All HIV\u20101\u2010infected women who received nevirapine as part of combination antiretroviral therapy (ART) during pregnancy were included in the study. Data on demographics, HIV infection risk, Centers for Disease Control and Prevention (CDC) status, surrogate markers at initiation of therapy, other medications hepatitis B and C virus coinfection and clinical data relating to potential toxicity were collated and analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifteen of 235 eligible women (6.4%) developed rash and eight (3.4%) developed hepatotoxicity, including four with coexistent rash, giving a combined incidence of 19 potential cases of nevirapine toxicity during pregnancy (8.1%). Alternative causes of rash\/hepatotoxicity were suspected in seven cases and only 10 mothers (5.8%) discontinued nevirapine. Of the 170 women who commenced nevirapine during this pregnancy, 13 (7.6%) developed rash and eight (4.7%) hepatotoxicity, a combined incidence of 10%. Only two of 65 women with nevirapine exposure prior to this pregnancy developed rash (3.1%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Nevirapine\u2010containing ART was well tolerated in this cohort of pregnant women. Although pregnancy did not appear to increase the risk of nevirapine\u2010associated toxicity compared to published adult data, CD<jats:sub>4<\/jats:sub> count may be less predictive of toxicity in pregnancy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2007.00433.x","type":"journal-article","created":{"date-parts":[[2007,1,15]],"date-time":"2007-01-15T18:35:19Z","timestamp":1168886119000},"page":"64-69","source":"Crossref","is-referenced-by-count":26,"title":["Safety of nevirapine in pregnancy"],"prefix":"10.1111","volume":"8","author":[{"given":"U","family":"Natarajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Pym","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Velisetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SG","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Hay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"De Ruiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GP","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,1,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411033311801"},{"key":"e_1_2_6_3_2","first-page":"795","article-title":"Intrapartum and neonatal single\u2010dose nevirapine compared with zidovudine for prevention of mother\u2010to\u2010child transmission of HIV\u20101 in Kampala, Uganda","volume":"354","author":"Guay L","year":"1999","journal-title":"HIVNET 012 randomised trail"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02383-7"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200108000-00017"},{"key":"e_1_2_6_6_2","first-page":"772","article-title":"PACTG 1022 Study Team. Maternal toxicity with continuous nevirapine in pregnancy","volume":"36","author":"Hitti J","year":"2004","journal-title":"results from PACTG 1022"},{"key":"e_1_2_6_7_2","unstructured":"BaylorM TruffaM GibbsN.Hepatic toxicity of antiretrovirals in HIV\u2010infected pregnant women: a review of the FDA's adverse event reporting system.11th Conference on Retroviruses and Opportunistic Infections. San Francisco CA February 2004 [Abstract 944]."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80105-7"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.101885"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00005"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107060-00007"},{"key":"e_1_2_6_12_2","volume-title":"Obstetric and Gynaecologic Dermatology","author":"Black M","year":"2002"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.8.1055-a"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1576\/toag.5.3.149"},{"key":"e_1_2_6_15_2","unstructured":"DieterichD SternJ RobinsonPet al. Analysis of four clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4+levels hepatitis B and C seropositivity and baseline liver function tests.1st International AIDS Society(IAS) Conference on HIV Pathogenesis and Treatment. Buenos Aires Argentina July 2001 [Abstract 44]."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/317536"},{"key":"e_1_2_6_17_2","unstructured":"MulchahyF WallaceE WoodsSet al. CD4 counts in pregnancy do not reflect the need for longterm HAART.13th Conference on Retroviruses and Opportunistic Infections. Denver CO February 2006 [Abstract 704b]."},{"key":"e_1_2_6_18_2","unstructured":"PhanuphakN TeeratakulpisarnS ApornpongT PhanuphakP.Comparison of hepatic and cutaneous toxicities in pregnant women with baseline CD4<250\u2003cells\/mm3versus those with CD4>250\u2003cells\/mm3receiving nevirapine (NVP)\u2010containing highly active anti\u2010retroviral therapy (HAART) for the prevention of mother\u2010to\u2010child transmission (PMTCT) in Thailand.7th International Congress on Drug Therapy in HIV Infection. Glasgow UK November 2004 [Abstract 322]."},{"key":"e_1_2_6_19_2","unstructured":"ThomasT AmornkulP MwidauJet alPreliminary findings: incidence of serious adverse events attributed to nevirapine among women enrolled in an ongoing trials using HAART to prevent mother\u2010to\u2010child HIV transmission.12th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2005 [Abstract 809]."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2005.05.015"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2007.00433.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2007.00433.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T02:19:47Z","timestamp":1696904387000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2007.00433.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1111\/j.1468-1293.2007.00433.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2007.00433.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}